Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: opportunities for integration and pitfalls to interpretation
Plasma circulating tumor DNA (ctDNA) represents short fragments of tumor-derived DNA
released into the bloodstream primarily from cancer cells undergoing apoptosis. In …
released into the bloodstream primarily from cancer cells undergoing apoptosis. In …
[HTML][HTML] Neuroendocrine prostate cancer drivers SOX2 and BRN2 confer differential responses to imipridones ONC201, ONC206, and ONC212 in prostate cancer cell …
C Purcell, PR Srinivasan… - American Journal of …, 2024 - pmc.ncbi.nlm.nih.gov
Objectives: Prostate cancer (PCa) is a leading cause of cancer death in men worldwide.
Approximately 30% of castrate-resistant PCa becomes refractory to therapy due to …
Approximately 30% of castrate-resistant PCa becomes refractory to therapy due to …